Wockhardt Ltd spurts 1.84%, rises for third straight session
NiveshIQ
NSE: WOCKPHARMA · Healthcare
Wockhardt Ltd.
₹1,916.50▲ ₹26.40 (+1.40%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on WOCKPHARMA. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Wockhardt Ltd.
Wockhardt Limited, a leading Indian pharmaceutical company, operates in the US, UK, Switzerland, Ireland, Russia, and internationally, manufacturing and trading pharmaceuticals, medicinal chemicals, and botanical products. The company's key revenue drivers include its branded formulations, which account for approximately 60% of its revenue, and its contract manufacturing business, which contributes around 30%. Wockhardt is developing several novel antibiotics, including ZAYNICH zidebactam/cefepime, FOVISCU, MIQNAF nafithromycin, and ODRATE, to address growing antibiotic resistance. The company also has a strong pipeline of insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products. Recent news has seen Wockhardt's share price surge, driven by strong price gains
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹2,798 Cr +5.50% | ₹3,012 Cr +7.60% | ₹3,373 Cr +12.00% |
| EBITDA Margin | 2.36% | 13.05% | 20.66% |
| Net Profit | -24.00% | -87.90% | ₹199.00 Cr -449.10% |
| EPS | ₹-31.42 | ₹-3.02 | ₹13.12 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Wockhardt Limited Revenue Breakdown – NSE:WOCKPHARMA
Wockhardt ASM लिस्ट में शामिल? Wockhardt Share Latest News, Wockpharma. Wockhardt Pharma Share Ryan Miller (k9ZqlIEp4a)
🔒
+ 3 more stories about Wockhardt Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q4FY26 results: revenue ₹965 Cr, PAT ₹164 Cr, EPS ₹10.23, EBITDA margin 28.0%. Growth context: revenue YoY +29.9%, PAT YoY -464.4%, revenue QoQ +8.7%, PAT QoQ +168.9%.
No specific capex or expansion announcements have been filed recently; demand conversion and margin discipline on the co...
Management's reluctance to provide forward-looking guidance underscores the Company's focus on executing its current gro...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for WOCKPHARMA
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track WOCKPHARMA alongside your other holdings
Unlock full WOCKPHARMA research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Wockhardt Ltd.?
NiveshIQ detects active intelligence signals for Wockhardt Ltd. (WOCKPHARMA) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Wockhardt Ltd.?
Wockhardt Ltd. operates in the Healthcare sector with a market capitalisation of ₹2,616,936.5L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.